Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 21, 2013; 19(43): 7561-7568
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7561
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7561
Has the risk of colorectal cancer in inflammatory bowel disease decreased?
Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagen, Denmark
Author contributions: Andersen NN collected the material and drafted the manuscript; and Jess T discussed the topic and revised the manuscript.
Correspondence to: Nynne Nyboe Andersen, MD, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. nyna@ssi.dk
Telephone: +45-32-683139 Fax: +45-32-683165
Received: August 28, 2013
Revised: October 20, 2013
Accepted: November 1, 2013
Published online: November 21, 2013
Processing time: 111 Days and 18 Hours
Revised: October 20, 2013
Accepted: November 1, 2013
Published online: November 21, 2013
Processing time: 111 Days and 18 Hours
Core Tip
Core tip: The increased risk of colorectal cancer in inflammatory bowel disease is well established. But what is the true magnitude of this increased risk, does the risk of colorectal cancer differ between ulcerative colitis and Crohn’s disease and what are the significant risk factors? Further, recent studies have indicated that the risk of colorectal cancer in patients with inflammatory bowel disease is decreasing over time, potentially due to improved treatment options that lower the inflammatory burden. These are some of the subjects that will be elucidated and discussed in this review.